The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19
To effectively respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an increasing number of researchers are focusing on the antiviral activity of cepharanthine (CEP), which is a clinically approved drug being used for over 70 years. This review aims to provide a brief overview of...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1098972/full |
| _version_ | 1827889714903908352 |
|---|---|
| author | Binbin Xia Li Zheng Yali Li Wenfang Sun Yang Liu Liushui Li Jingyao Pang Jing Chen Jiaxin Li Hua Cheng |
| author_facet | Binbin Xia Li Zheng Yali Li Wenfang Sun Yang Liu Liushui Li Jingyao Pang Jing Chen Jiaxin Li Hua Cheng |
| author_sort | Binbin Xia |
| collection | DOAJ |
| description | To effectively respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an increasing number of researchers are focusing on the antiviral activity of cepharanthine (CEP), which is a clinically approved drug being used for over 70 years. This review aims to provide a brief overview of CEP and summarize its recent findings in quantitative analysis, pharmacokinetics, therapeutic potential, and mechanism in antiviral and anti-SARS-CoV-2 activity. Given its remarkable capacity against SARS-CoV-2 infection in vitro and in vivo, with its primary target organ being the lungs, and its good pharmacokinetic profile; mature and stable manufacturing technique; and its advantages of safety, effectiveness, and accessibility, CEP has become a promising drug candidate for treating COVID-19 despite being an old drug. |
| first_indexed | 2024-03-12T20:59:34Z |
| format | Article |
| id | doaj.art-f54ea0609a11481581458cf7af0d7894 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-12T20:59:34Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-f54ea0609a11481581458cf7af0d78942023-07-31T10:00:56ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-07-011410.3389/fphar.2023.10989721098972The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19Binbin Xia0Li Zheng1Yali Li2Wenfang Sun3Yang Liu4Liushui Li5Jingyao Pang6Jing Chen7Jiaxin Li8Hua Cheng9Department of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, ChinaDepartment of Pharmacy, China Aerospace Science & Industry Corporation 731 Hospital, Beijing, ChinaDepartment of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Beijing Hospital, National Center of Gerontology, Beijing, ChinaDepartment of Pharmacy, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, ChinaTo effectively respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an increasing number of researchers are focusing on the antiviral activity of cepharanthine (CEP), which is a clinically approved drug being used for over 70 years. This review aims to provide a brief overview of CEP and summarize its recent findings in quantitative analysis, pharmacokinetics, therapeutic potential, and mechanism in antiviral and anti-SARS-CoV-2 activity. Given its remarkable capacity against SARS-CoV-2 infection in vitro and in vivo, with its primary target organ being the lungs, and its good pharmacokinetic profile; mature and stable manufacturing technique; and its advantages of safety, effectiveness, and accessibility, CEP has become a promising drug candidate for treating COVID-19 despite being an old drug.https://www.frontiersin.org/articles/10.3389/fphar.2023.1098972/fullcepharanthineantivirusanti-SARS-CoV-2pharmacokineticsresearch progress |
| spellingShingle | Binbin Xia Li Zheng Yali Li Wenfang Sun Yang Liu Liushui Li Jingyao Pang Jing Chen Jiaxin Li Hua Cheng The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19 Frontiers in Pharmacology cepharanthine antivirus anti-SARS-CoV-2 pharmacokinetics research progress |
| title | The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19 |
| title_full | The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19 |
| title_fullStr | The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19 |
| title_full_unstemmed | The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19 |
| title_short | The brief overview, antivirus and anti-SARS-CoV-2 activity, quantitative methods, and pharmacokinetics of cepharanthine: a potential small-molecule drug against COVID-19 |
| title_sort | brief overview antivirus and anti sars cov 2 activity quantitative methods and pharmacokinetics of cepharanthine a potential small molecule drug against covid 19 |
| topic | cepharanthine antivirus anti-SARS-CoV-2 pharmacokinetics research progress |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1098972/full |
| work_keys_str_mv | AT binbinxia thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT lizheng thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT yalili thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT wenfangsun thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT yangliu thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT liushuili thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT jingyaopang thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT jingchen thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT jiaxinli thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT huacheng thebriefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT binbinxia briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT lizheng briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT yalili briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT wenfangsun briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT yangliu briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT liushuili briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT jingyaopang briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT jingchen briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT jiaxinli briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 AT huacheng briefoverviewantivirusandantisarscov2activityquantitativemethodsandpharmacokineticsofcepharanthineapotentialsmallmoleculedrugagainstcovid19 |